Exploring the Peptide Economy Beyond GLP-1 Advancements | Retatrutide News

The peptide economy is expanding beyond the current GLP-1 receptor agonist boom. Eli Lilly is advancing its metabolic pipeline with new GLP-1 therapies.
Market News · October 23, 2026